The effects of low levels of dystrophin on mouse muscle function and pathology

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  van Putten, Maaike ^a   Hulsker, Margriet ^a   Nadarajah, Vishna Devi ^a   van Heiningen, Sandra H ^a   van Huizen, Ella ^a   van Iterson, Maarten ^a   Admiraal, Peter ^a   Messemaker, Tobias ^a   den Dunnen, Johan T ^a   't Hoen, Peter A C ^a   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DYSTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FUNCTIONAL ASSESSMENT; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC MARKER; HISTOPATHOLOGY; MALE; MOUSE; MUSCLE CELL; MUSCLE FUNCTION; MUSCULAR DYSTROPHY; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREADMILL EXERCISE; X CHROMOSOME INACTIVATION; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; CHEMISTRY; MUSCLE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; DYSTROPHIN; FEMALE; MICE; MUSCLE FIBERS, SKELETAL; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; X CHROMOSOME INACTIVATION;

EID: 84857126451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031937     Document Type: Article

References (42)

1. Hoffman EP, Brown RH Jr, Kunkel LM, (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
2. Aartsma-Rus A, van Deutekom JC, Fokkema IF, van Ommen GJ, den Dunnen JT, (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34: 135-144.
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM, (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
4. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, et al. (1988) Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 318: 1363-1368.
5. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47: 430-444.
6. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
7. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
8. Aartsma-Rus A, den Dunnen JT, van Ommen GJ, (2010) New insights in gene-derived therapy: the example of Duchenne muscular dystrophy. Ann N Y Acad Sci 1214: 199-212.
9. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, et al. (2010) Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437.
10. Malik V, Rodino-Klapac LR, Viollet L, Mendell JR, (2010) Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord 3: 379-389.
11. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
12. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
13. Pegoraro E, Schimke RN, Garcia C, Stern H, Cadaldini M, et al. (1995) Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 45: 677-690.
14. Schmidt-Achert M, Fischer P, Muller-Felber W, Mudra H, Pongratz D, (1993) Heterozygotic gene expression in endomyocardial biopsies: a new diagnostic tool confirms the Duchenne carrier status. Clin Investig 71: 247-253.
15. Ogata H, Nakagawa H, Hamabe K, Hattori A, Ishikawa Y, et al. (2000) A female carrier of Duchenne muscular dystrophy complicated with cardiomyopathy. Intern Med 39: 34-38.
16. Bostick B, Yue Y, Long C, Duan D, (2008) Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102: 121-130.
17. Tanaka H, Ikeya K, Ozawa E, (1990) Difference in the expression pattern of dystrophin on the surface membrane between the skeletal and cardiac muscles of mdx carrier mice. Histochemistry 93: 447-452.
18. Boyd Y, Buckle V, Holt S, Munro E, Hunter D, et al. (1986) Muscular dystrophy in girls with X;autosome translocations. J Med Genet 23: 484-490.
19. Azofeifa J, Voit T, Hubner C, Cremer M, (1995) X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. Hum Genet 96: 167-176.
20. Lupski JR, Garcia CA, Zoghbi HY, Hoffman EP, Fenwick RG, (1991) Discordance of muscular dystrophy in monozygotic female twins: evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of Duchenne dystrophy. Am J Med Genet 40: 354-364.
21. Soltanzadeh P, Friez MJ, Dunn D, von NA, Gurvich OL, et al. (2010) Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord 20: 499-504.
22. Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, et al. (1989) Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 39: 1011-1017.
23. Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, et al. (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 17: 913-918.
24. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, (1993) Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch Dis Child 68: 632-636.
25. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, et al. (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4: 1251-1258.
26. Rafael JA, Sunada Y, Cole NM, Campbell KP, Faulkner JA, et al. (1994) Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet 3: 1725-1733.
27. Dunant P, Larochelle N, Thirion C, Stucka R, Ursu D, et al. (2003) Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice. Mol Ther 8: 80-89.
28. Stillwell E, Vitale J, Zhao Q, Beck A, Schneider J, et al. (2009) Blastocyst injection of wild type embryonic stem cells induces global corrections in mdx mice. PLoS One 4: e4759.
29. Li D, Yue Y, Duan D, (2008) Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol 172: 1332-1341.
30. Brockdorff N, Ashworth A, Kay GF, Cooper P, Smith S, et al. (1991) Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. Nature 351: 329-331.
31. Senner CE, Brockdorff N, (2009) Xist gene regulation at the onset of X inactivation. Curr Opin Genet Dev 19: 122-126.
32. Newall AE, Duthie S, Formstone E, Nesterova T, Alexiou M, et al. (2001) Primary non-random X inactivation associated with disruption of Xist promoter regulation. Hum Mol Genet 10: 581-589.
33. van Putten M, Kumar D, Hulsker M, Hoogaars WMH, Plomp JJ, et al. (2012) Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul Disord in press.
34. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39: 591-602.
35. van Erp C, Loch D, Laws N, Trebbin A, Hoey AJ, (2010) Timeline of cardiac dystrophy in 3-18-month-old MDX mice. Muscle Nerve 42: 504-513.
36. Turk R, Sterrenburg E, de Meijer EJ, van Ommen GJ, den Dunnen JT, et al. (2005) Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiling. BMC Genomics 6: 98.
37. Nadarajah VD, van PM, Chaouch A, Garrood P, Straub V, et al. (2011) Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 21: 569-578.
38. Sharp PS, Jee H, Wells DJ, (2011) Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther 19: 165-171.
39. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67: 771-780.
40. van Putten M, de Winter CL, van Roon-Mom W, van Ommen GJ, 't Hoen PA, et al. (2010) A 3 months mild functional test regime does not affect disease parameters in young mdx mice. Neuromuscul Disord 20: 273-280.
41. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, et al. (2009) In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11: 257-266.
42. Ramakers C, Ruijter JM, Deprez RH, Moorman AF, (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62-66.